(Q30328005)

18 June 2017

1 reference

title

Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. (English)

1 reference

18 June 2017

Klein M

1

1 reference

PubMed ID

11257335

18 June 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

18 June 2017

1 reference

18 June 2017

19

1 reference

18 June 2017

17-19

1 reference

18 June 2017

2210-2215

1 reference

Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?

18 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

T lymphocyte responses in HIV-1 infection: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Protective immunity induced by live attenuated simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Live attenuated AIDS viruses as vaccines: promise or peril?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

A role for carbohydrates in immune evasion in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Fusion-competent vaccines: broad neutralization of primary isolates of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Vaccination with Rev and Tat against AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

1 reference

7 January 2021

Alphavirus-based expression vectors: strategies and applications

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Alloimmunization as a strategy for vaccine design against HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Oral somatic transgene vaccination using attenuated S. typhimurium.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

AIDS. Boosting immunity to HIV--can the virus help?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900547-8

7 January 2021

10.1016/S0264-410X(00)00547-8

Identifiers

DOI

1 reference

18 June 2017

1 reference

PubMed ID

11257335